Prostate Cancer: Page 2

Some prostate cancer policies drive overdiagnosis, argue experts

By Elissa Wolfson

Prostate cancer test-by-request policies have led to excessive PSA testing for asymptomatic men, overdiagnosis, overtreatment, and inequity, contend experts.

May 18, 2023

EU project aims to reduce prostate cancer via early detection

By Elissa Wolfson

A new three-year EU project aims to reduce prostate cancer mortality through smart early detection, while avoiding overdiagnosis and overtreatment.

April 25, 2023

MDxHealth nabs reimbursement for prostate cancer risk test

By LabPulse.com staff writers

The firm's Select mdx test will now be reimbursed in the U.S. for Medicare patients who meet coverage conditions under a specific, foundational Local Coverage Determination (LCD).

April 20, 2023

Veracyte announces data for prostate cancer classifier in micrometastatic disease

By LabPulse.com staff writers

The published data show that the Decipher Prostate scores for patients with high-risk and very high-risk disease were highly correlated with the upstaging predictions by a clinically-validated algorithm.

April 17, 2023

Older males may be overscreened for prostate cancer

By Elissa Wolfson

Researchers have found that older males were often overscreened for prostate cancer, despite national guidelines outlining the limited value of such screening.

April 11, 2023

Racial groups negatively impacted by exclusion from cancer research

By Elissa Wolfson

Researchers are calling for greater inclusion of people with African ancestry in genomic research to improve prostate cancer outcome disparities.

March 10, 2023

Active surveillance on the rise for low-risk prostate cancer

By Elissa Wolfson

A large study indicates that active surveillance rates for management of low-risk prostate cancer are rising nationally, but are still not optimal.

March 2, 2023

Bio-Techne's prostate test granted expanded Medicare coverage

By LabPulse.com staff writers

The updated Medicare policy covers an annual ExoDx Prostate Test for men who have already had a negative biopsy but are thought to be at high risk for prostate cancer and are considering a repeat biopsy.

February 24, 2023

Cleveland Diagnostics, Quest Diagnostics expand access to blood-based prostate cancer test

By LabPulse.com staff writers

When physicians order the IsoPSA prostate cancer test, their patients will provide blood specimens at a Quest patient service center. Quest will transport the blood samples for testing at a Cleveland Diagnostics’ laboratory.

February 13, 2023

Oxford BioDynamics announces study results for prostate screening blood test

By LabPulse.com staff writers

The published results from the multidisciplinary PROSTAGRAM study show that the PSE test had a 92% positive and 94% negative predictive value and an accuracy of 94%.

February 7, 2023

In pilot study, liquid biopsy test differentiates between localized and metastatic cancer to inform tailored treatment

By Nick Paul Taylor

Cedars-Sinai Cancer researchers are developing a microfluidic device with a nanosurface as part of a blood test to inform treatment decisions.

February 3, 2023

Avenda Health gets FDA 510(k) clearance for iQuest prostate cancer platform

By LabPulse.com staff writers

The iQuest platform provides physicians with a 3D visualization, enabling treatment decisions that consider the extent of the cancer rather than treating the whole organ.

December 8, 2022

Previous Page

Page 2 of 8

Next Page